Ocugen, Inc. (OCGN) News
Follow Ocugen, Inc. (OCGN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Ocugen to Participate in Upcoming Scientific Conferences
MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) NASDAQ:OCGN, a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company wil
NEWS | Sep 30, 2026, 11:08 AM UTC
L
Ocugen to Participate in Upcoming October Investor and Industry Conferences
MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) NASDAQ:OCGN, a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of its
NEWS | Sep 29, 2026, 11:08 AM UTC
L
Weekly Recap: Cash runway through 2028 and OCU400 Phase 3/BLA in 2027
Ocugen Inc (NASDAQ:OCGN) closed the quarter with $100.1M in cash and says recent financing extends its runway through 2028 as shares trade just above $1; the company is advancing OCU400 toward topline Phase 3 results in
EQUITY | Sep 28, 2026, 11:04 AM UTC
L
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
Ocugen (OCGN) was in the spotlight on Friday after the biotech firm announced that its experimental gene therapy for an eye disorder received provisional approval and priority designation in the Bahamas, marking another
NEWS | Sep 25, 2026, 12:52 PM UTC
L
Ocugen Shares Rise on Provisional Approval for Retinitis Pigmentosa Treatment in Bahamas
By Kelly CloonanShares of Ocugen ticked higher after its treatment for retinitis pigmentosa, or RP, a type of genetic eye disorder, got provisional approval and priority designation from regulators in the Bahamas.The sto
EQUITY | Sep 25, 2026, 11:49 AM UTC
L
Ocugen, Inc. (OCGN) Gets Provisional, Priority LARTA Nod for OCU400 in The Bahamas
Ocugen received Provisional Approval and Priority Designation under The Bahamas' LARTA to provide OCU400 for retinitis pigmentosa via an Early Access Program, aiming to treat the first patient within 90 days following fu
NEWS | Sep 25, 2026, 11:09 AM UTC
L
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
MALVERN, Pa., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) NASDAQ:OCGN, a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that OCU400 has been gran
NEWS | Sep 25, 2026, 11:08 AM UTC
L
Ocugen Is Maintained at Buy by HC Wainwright & Co.
Ratings actions from Benzinga
EQUITY | Sep 10, 2026, 10:38 AM UTC
M
Ocugen falls after interim trial data disappoints
Ocugen fell nearly 14% after a disappointing interim analysis from a Phase 2/3 trial for OCU410ST, its experimental therapy for Stargardt disease.
EQUITY | Sep 09, 2026, 05:01 PM UTC
M
Ocugen doses first patient in Phase 3 OCU410 trial
Ocugen said the first patient was dosed in the global Phase 3 registrational trial of OCU410 for geographic atrophy. It also said the DMC recommended completing 8-month follow-up in the OCU410ST interim review.
REGULATION | Sep 08, 2026, 09:34 PM UTC
M
Ocugen first patient dosed in Phase 3 registrational trial of OCU410
Ocugen says the first patient has been dosed in its Phase 3 registrational trial of OCU410 for geographic atrophy secondary to dry age-related macular degeneration.
EQUITY | Sep 01, 2026, 11:02 AM UTC
L
Ocugen (OCGN) to participate in upcoming September investor conferences
Ocugen says it will participate in upcoming September investor and industry conferences, without providing any event details or financial figures in the announcement.
EQUITY | Aug 25, 2026, 11:02 AM UTC
L
OCGN - Ocugen Provides Business Update with Second Quarter 2026 Financial Results
OCGN - Ocugen Provides Business Update with Second Quarter 2026 Financial Results
EARNINGS | Aug 06, 2026, 11:02 AM UTC
L
Ocugen to Participate in Investor Conferences
Ocugen participates in August investor conferences
EQUITY | Jul 31, 2026, 11:02 AM UTC
H
Ocugen Gets FDA RMAT Designation
Ocugen receives RMAT designation for OCU410
REGULATION | Jul 29, 2026, 11:01 AM UTC